Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Lucid Diagnostics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REPORT INCLUDES NEARLY 12,000 PATIENTS WHO UNDERWENT LUCID'S ESOGUARD ESOPHAGEAL DNA TEST ON SAMPLES COLLECTED USING ITS ESOCHECK ESOPHAGEAL CELL COLLECTION DEVICE REAL-WORLD DATA CONFIRM EXCELLENT TECHNICAL PERFORMANCE, VERY RAPID CELL-COLLECTION TIMES, AND APPROPRIATE PHYSICIAN USE, CONSISTENT WITH PREVIOUSLY PUBLISHED STUDIES NEW YORK , DEC. 9, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED NEW DATA FROM THE LARGEST REPORTED REAL-WORLD EXPERIENCE OF NON-ENDOSCOPIC ESOPHAGEAL PRECANCER (BARRETT'S ESOPHAGUS OR BE) DETECTION, WHICH EVALUATED ITS ESOGUARD ESOPHAGEAL DNA TEST AND ESOCHECK ESOPHAGEAL CELL COLLECTION DEVICE . THE MANUSCRIPT, ENTITLED NON-ENDOSCOPIC SCREENING FOR BARRETT'S ESOPHAGUS USING A DNA METHYLATION-BASED ASSAY: 18-MONTH REAL-WORLD EXPERIENCE IN 11,991 PATIENTS , IS CURRENTLY AVAILABLE ON THE LEADING HEALTH SCIENCES PREPRINT SERVER, MEDRXIV, WHILE UNDERGOING PEER REVIEW FOR PUBLICATION.

LUCID DIAGNOSTICS ANNOUNCES POSITIVE DATA FROM THE LARGEST REPORTED REAL-WORLD EXPERIENCE OF ESOPHAGEAL PRECANCER DETECTION

RECOGNIZED AS THE LEADING COMPANY IN ITS SIZE CATEGORY IN PROGRAM HONORING THE TOP WORKPLACES ACROSS THE DIAGNOSTICS AND PRECISION-MEDICINE SECTORS NEW YORK , NOV. 20, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THAT IT HAS BEEN NAMED THE WINNER IN ITS COMPANY SIZE CATEGORY OF THE GENOMEWEB 2025 BEST PLACES TO WORK PROGRAM, ONE OF FIVE TOP-RANKING HONOREES ACROSS THE LIFE SCIENCES RESEARCH, DIAGNOSTICS AND PRECISION MEDICINE SECTORS. GENOMEWEB IS THE LEADING NEWS ORGANIZATION SERVING THE GLOBAL COMMUNITY OF PROFESSIONALS IN MOLECULAR BIOLOGY RESEARCH AND MOLECULAR DIAGNOSTICS.

LUCID DIAGNOSTICS NAMED A GENOMEWEB 2025 BEST PLACES TO WORK TOP-RANKING HONOREE

NEW YORK , NOV. 13, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE CANACCORD GENUITY MEDTECH, DIAGNOSTICS AND DIGITAL HEALTH & SERVICES FORUM, BEING HELD NOVEMBER 20, 2025 IN NEW YORK CITY. DENNIS MCGRATH, LUCID'S CHIEF FINANCIAL OFFICER, WILL BE AVAILABLE FOR ONE-ON-ONE MEETINGS WITH INVESTORS.

LUCID DIAGNOSTICS TO PARTICIPATE IN THE CANACCORD GENUITY MEDTECH, DIAGNOSTICS AND DIGITAL HEALTH & SERVICES FORUM

VERIS HEALTH LAUNCHED COMMERCIAL PHASE OF STRATEGIC PARTNERSHIP AND RELAUNCHED DEVELOPMENT OF IMPLANTABLE PHYSIOLOGICAL MONITOR PAVMED SIGNED LETTER OF INTENT (LOI) TO LICENSE GROUNDBREAKING ENDOSCOPIC ESOPHAGEAL IMAGING TECHNOLOGY CONFERENCE CALL AND WEBCAST TO BE HELD TODAY, NOVEMBER 13, AT 8:30 AM EST NEW YORK , NOV. 13, 2025 /PRNEWSWIRE/ -- PAVMED INC. (NASDAQ: PAVM) ("PAVMED" OR THE "COMPANY"), A DIVERSIFIED COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY, OPERATING IN THE MEDICAL DEVICE, DIAGNOSTICS, AND DIGITAL HEALTH SECTORS, TODAY PROVIDED A BUSINESS UPDATE FOR THE COMPANY AND ITS SUBSIDIARIES, LUCID DIAGNOSTICS INC. (NASDAQ: LUCD) ("LUCID") AND VERIS HEALTH INC. ("VERIS"), AND REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025. CONFERENCE CALL AND WEBCAST THEWEBCASTWILL TAKE PLACE ON THURSDAY, NOVEMBER 13, 2025, AT 8:30 AM AND IS ACCESSIBLE IN THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT PAVMED.COM.

PAVMED PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

PROCESSED 2,841 ESOGUARD TESTS AND RECOGNIZED 3Q25 REVENUE OF $1.2 MILLION, ENDING QUARTER WITH OVER $47 MILLION IN PROFORMA CASH AND EXTENDING RUNWAY THROUGH 2026 AND WELL PAST UPCOMING REIMBURSEMENT MILESTONES MULTI-JURISDICTIONAL CONTRACTOR ADVISORY COMMITTEE (CAC) MEETING ON MEDICARE LOCAL COVERAGE DETERMINATION (LCD) FOR LUCID'S ESOGUARD YIELDED UNANIMOUS EXPERT CONSENSUS SUPPORTING MEDICARE COVERAGE CONFERENCE CALL AND WEBCAST TO BE HELD TODAY, NOVEMBER 12, AT 8:30 AM EST NEW YORK , NOV. 12, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY") A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM)("PAVMED"), TODAY PROVIDED A BUSINESS UPDATE FOR THE COMPANY AND REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025. CONFERENCE CALL AND WEBCAST THE WEBCAST WILL TAKE PLACE ON WEDNESDAY, NOVEMBER 12, 2025, AT 8:30 AM AND WILL BE ACCESSIBLE IN THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT LUCIDDX.COM.

LUCID DIAGNOSTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

CONFERENCE CALL AND WEBCAST AT 8:30 AM EASTERN TIME NEW YORK , OCT. 30, 2025 /PRNEWSWIRE/ -- PAVMED INC. (NASDAQ: PAVM) ("PAVMED" OR THE "COMPANY"), A DIVERSIFIED COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY, OPERATING IN THE MEDICAL DEVICE, DIAGNOSTICS, AND DIGITAL HEALTH SECTORS, TODAY ANNOUNCED THAT IT WILL HOST A BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON THURSDAY, NOVEMBER 13, 2025, AT 8:30 AM ET. DURING THE CALL, LISHAN AKLOG, M.D.

PAVMED TO HOLD A BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON NOVEMBER 13, 2025

CONFERENCE CALL AND WEBCAST AT 8:30 AM EASTERN TIME NEW YORK , OCT. 29, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY") A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THAT IT WILL HOST A BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON WEDNESDAY, NOVEMBER 12, 2025, AT 8:30 AM ET. DURING THE CALL, LISHAN AKLOG, M.D.

LUCID DIAGNOSTICS TO HOLD A BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON NOVEMBER 12, 2025

NEW YORK , OCT. 15, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE 2025 MAXIM GROWTH SUMMIT, BEING HELD OCTOBER 22-23, 2025 IN NEW YORK CITY. DENNIS MCGRATH, LUCID'S CHIEF FINANCIAL OFFICER, WILL HOST ONE-ON-ONE MEETINGS THROUGHOUT THE CONFERENCE.

LUCID DIAGNOSTICS TO PARTICIPATE IN THE 2025 MAXIM GROWTH SUMMIT

GROWTH-FOCUSED HEALTHCARE EXECUTIVE BRINGS 40 YEARS OF EXECUTIVE LEADERSHIP EXPERIENCE ACROSS MULTIPLE INDUSTRY SECTORS NEW YORK , SEPT. 25, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THE APPOINTMENT OF ACCOMPLISHED HEALTHCARE EXECUTIVE JOHN R.

LUCID DIAGNOSTICS APPOINTS HEALTHCARE INDUSTRY VETERAN JOHN R. PALUMBO TO BOARD OF DIRECTORS

SCELFO TO STRENGTHEN AND SCALE LUCID'S MARKET ACCESS INFRASTRUCTURE AHEAD OF KEY UPCOMING REIMBURSEMENT MILESTONESINCLUDING MEDICARE COVERAGE FOR ESOGUARDAND TO ACCELERATE COMMERCIAL COVERAGE EXPANSION NEW YORK , SEPT. 16, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THE APPOINTMENT OF DANIELLE SCELFO AS SENIOR VICE PRESIDENT, MARKET ACCESS & GOVERNMENT AFFAIRS, REPORTING TO THE CHIEF EXECUTIVE OFFICER.

Lucid Diagnostics Inc.

LUCD

Price

Financial Reports

No items found.

Press Releases

Lucid Diagnostics Inc.

LUCD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LUCD